Tumour-agnostic drugs in paediatric cancers.
View/ Open
ICR Author
Author
Chisholm, JC
Carceller, F
Marshall, LV
Type
Other
Metadata
Show full item recordAbstract
The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children.
Collections
Subject
Humans
Neoplasms
Pyrazoles
Pyrimidines
Oncogene Proteins, Fusion
Antineoplastic Agents
Pharmaceutical Preparations
Protein Kinase Inhibitors
Drug Approval
Pediatrics
Adult
Child
Research team
Sarcoma Clinical Trials in children and young people
Sarcoma Clinical Trials in children and young people
Language
eng
Date accepted
2020-03-01
Citation
British journal of cancer, 2020, 122 (10), pp. 1425 - 1427